Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection

Summary

The main purpose of the study is to evaluate the safety of oral auranofin, a gold compound, in patients with HIV infection whose viral load has been suppressed by antiretroviral therapy for no less than 3 years and have a CD4+ cell count over 500 cells/uL

Timeline

Start

—

Primary completion

2016-01

Completion

2017-01

Drugs

Indications